Introduction: Vulva cancer is an uncommon disease. It represents about 3% to 5% of gynecologic cancers worldwide, but its incidence is increasing with age and Human Papilloma Virus (HPV) and HIV infection. In Cameroon, annual number of new cases was 52 in 2020. Surgery is the treatment of choice and it is only realized in teaching hospitals. Yaounde Gynaeco-Obstetric and Pediatric Hospital (YGOPH) is one of the centers where cancer cases are referred to. Case Report: We report a case of a 49-year-old woman, gravida 2 para 1, known HIV positive for twenty years, who complained of vulva pruritis for last two years. Six months after the onset of pruritis, she presented a local swelling of both labia majora, which got ulcerated on the right, associated with severe pain. On clinical examination, she was in good general condition with a 3 × 3.5 cm ulcerated, budding mass in the middle third of the right labia majora, approaching the midline formed by the vaginal orifice, with no locoregional infiltration (vagina, bladder, urethra, anus and rectum). The left labia majora was abnormally thickened by about 1 cm, with no palpable mass. There were no palpable inguinal lymph nodes. Punch biopsy revealed an invasive non keratinizing carcinoma of the vulva. MRI showed no suspicious lymph nodes or invasion of pelvic organs. The patient underwent radical vulvectomy with bilateral inguinofemoral lymph nodes dissection. The postoperative period was uneventful, and anatomopathological examination confirmed vulvar carcinoma without lymph node invasion or lymphovascular emboli, and excision margins were in sano. No adjuvant treatment was therefore initiated. Conclusion: Vulva cancer is extremely rare, and frequently associated with HIV infection. Any suspected vulvar lesion should be biopsied. Although other treatment modalities are available, surgery remains the cornerstone of its management.
References
[1]
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: Globo Can Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[2]
De Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D. and Plummer, M. (2012) Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis. The Lancet Oncology, 13, 607-615. https://doi.org/10.1016/S1470-2045(12)70137-7
[3]
Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I. and Bray, F. (2020) Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. https://gco.iarc.fr/today
[4]
Enow-Orock, G., Mbu, R., Ngowe, N.M., Tabung, F.K., Mboudou, E., Ndom, P., Nkele, N., Takang, W., Essame-Oyono, J.L. and Doh, A. (2006) Gynecological Cancer Profile in the Yaounde Population, Cameroon. Clinics in Mother and Child health, 3, 437-444.
[5]
Doh, A.S. and Shasha, W. (1993) Carcinoma of the Vulva in Yaounde, Cameroon. International Journal of Gynecology & Obstetrics, 45, 63-64.
[6]
Alkatout, I., Schubert, M., Garbrecht, N., Weigel, M.T., Jonat, W., Mundhenke, C. and Günther, V. (2015) Vulvar Cancer: Epidemiology, Clinical Presentation, and Management Options. International Journal of Women’s Health, 20, 305-313. https://doi.org/10.2147/IJWH.S68979
[7]
Lipińska, J., Stefanowicz, M., Waśniewski, T., Martyn, P. and Loewenau-Samusionek, K. (2013) Cancer of the Vulva in a 28-Year-Old Woman. Polish Annals of Medicine, 20, 132-134. https://doi.org/10.1016/j.poamed.2013.10.003
[8]
Smith, J.S., Backes, D.M., Hoots, B.E., Kurman, R.J. and Pimenta, J.M. (2009) Human Papillomavirus Type-Distribution in Vulvar and Vaginal Cancers and Their Associated Precursors. Obstetrics & Gynecology, 113, 917-924. https://doi.org/10.1097/AOG.0b013e31819bd6e0
[9]
Majewski, S., Pniewski, T. and Goyal-Stec, M. (2005) Rola wiruso’w brodawczaka w rozwoju zmian łagodnych i złos’liwych okolicy narza d’ow płciowych. The Role of Human Papillomavirus in the Development of Benign and Malignant Lesions of the Genital Area. Zakazenia, 6, 58-62.
[10]
Sideri, M., Jones, R.W., Wilkinson, E.J., Preti, M., Heller, D.S., Scurry, J., et al. (2005) Squamous Vulvar Intraepithelial Neoplasia: 2004 Modified Terminology, ISSVD Vulvar Oncology Subcommittee. Journal of Reproductive Medicine, 50, 807-810.
[11]
Preti, M., Joura, E., Vieira-Baptista, P., Van Beurden, M., Bevilacqua, F., Bleeker, M.C.G., et al. (2022) The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Preinvasive Vulvar Lesions. Journal of Lower Genital Tract Disease, 26, 229-244. https://doi.org/10.1097/LGT.0000000000000683
[12]
Van de Nieuwenhof, H.P., Massuger, L.F.A.G., van der Avoort, I.A.M., Bekkers, R.L.M., Casparie, M., Abma, W., et al. (2009) Vulvar Squamous Cell Carcinoma Development after Diagnosis of VIN Increases with Age. European Journal of Cancer, 45, 851-856. https://doi.org/10.1016/j.ejca.2008.11.037
[13]
Lebreton, M., Carton, I., Brousse, S., Lavoué, V., Body, G., Levêque, J., et al. (2020) Vulvar Intraepithelial Neoplasia: Classification, Epidemiology, Diagnosis, and Management. Journal of Gynecology Obstetrics and Human Reproduction, 49, Article 101801. https://doi.org/10.1016/j.jogoh.2020.101801
[14]
Palmer, J.E. and Gillespie, A.M. (2010) Diagnosis and Management of Squamous-Cell vulval Carcinoma. Gynaecological Malignancies, 15, 20-25. https://doi.org/10.1002/tre.132
[15]
Hunter, D.J.S. (1975) Carcinoma of the Vulva: A Review of 361 Patients. Gynecologic Oncology, 3, 117-123. https://doi.org/10.1016/0090-8258(75)90072-4
[16]
Gaillard, A.L., Renaud, T., Brocard, C., Deleau, F., Petit, A., Guyon, F., et al. (2023) Cancers de la vulve: Dernières actualités et nouvelle classification Figo 2021. Imagerie de la Femme, 33, 1‑8. https://doi.org/10.1016/j.femme.2022.11.001
[17]
Oonk, M.H.M., Planchamp, F., Baldwin, P., et al. (2023) European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer-Update 2023. International Journal of Gynecological Cancer, 33, 1023-1043. https://doi.org/10.1136/ijgc-2023-004486
[18]
Olawaiye, A.B., Cotler, J., Cuello, M.A., Bhatla, N., Okamoto, A., Wilailak, S., et al. (2021) FIGO Staging for Carcinoma of the Vulva: 2021 Revision. International Journal of Gynecology & Obstetrics, 155, 43‑47. https://doi.org/10.1002/ijgo.13880
[19]
Brierley, J.D., Gospodarowicz, M.K. and Wittekind, C. (2017) TNM Classification of Malignant Tumours. 8th Edition. Wiley. https://www.uicc.org/resources/tnm-classification-malignant-tumours-8th-edition
[20]
Holleczek, B., Sehouli, J. and Barinoff, J. (2017) Vulvar Cancer in Germany: Increase in Incidence and Change in Tumour Biological Characteristics from 1974 to 2013. Acta Oncologica, 57, 324-330. https://doi.org/10.1080/0284186X.2017.1360513
[21]
Buttmann-Schweiger, N., Barinoff, J., Waldmann, A. et al. (2019) Epidemiologie der krebserkrankungen von vulva und vagina in deutschland. Der Onkologe, 25, 396-403. https://doi.org/10.1007/s00761-019-0565-6
[22]
Nkyekyer, K. (2000) Pattern of Gynaecological Cancers in Ghana. East African Medical Journal, 77, 534-538. https://doi.org/10.4314/eamj.v77i10.46708
[23]
De Hullu, J.A. and van der Zee, A.G.J. (2006) Surgery and Radiotherapy in Vulvar Cancer. Critical Reviews in Oncology/Hematology, 60, 38-58. https://doi.org/10.1016/j.critrevonc.2006.02.008
[24]
Taussig, F.J. (1940) Cancer of the Vulva: An Analysis of 155 Cases. American Journal of Obstetrics & Gynecology, 40, 764-779. https://doi.org/10.1016/S0002-9378(15)30802-4
[25]
Way, S. (1960) Carcinoma of the Vulva. American Journal of Obstetrics & Gynecology, 79, 692-697. https://doi.org/10.1016/0002-9378(60)90626-8
[26]
De Hullu, J.A., Hollema, H., Lolkema, S., et al. (2002) Vulvar Carcinoma. The Price of Less Radical Surgery. Cancer, 95, 2331-2338. https://doi.org/10.1002/cncr.10969
[27]
Chan, J.K., Sugiyama, V., Pham, H., et al. (2007) Margin Distance and Other Clinicopathologic Prognostic Factors in Vulvar Carcinoma: A Multivariate Analysis. Gynecologic Oncology, 104, 636-641. https://doi.org/10.1016/j.ygyno.2006.10.004
[28]
Raspagliesi, F., Hanozet, F., Dittoa, A., Solima, E., Zanaboni, F., Vecchione, F. and Kusamura, S. (2006) Clinical and Pathological Factors in Squamous Cell Carcinoma of the Vulva. Gynecologic Oncology, 102, 333-337. https://doi.org/10.1016/j.ygyno.2005.12.027
[29]
Baiocchi, G., Silva Cestari, F.M., Rocha, R.M., et al. (2013) Prognostic Value of the Number and Laterality of Metastatic Inguinal Lymph Nodes in Vulvar Cancer: Revisiting the FIGO Staging System. European Journal of Surgical Oncology, 39, 780-785. https://doi.org/10.1016/j.ejso.2013.03.004
[30]
Woelber, L., Kock, L., Gieseking, F., et al. (2011) Clinical Management of Primary Vulvar Cancer. European Journal of Cancer, 47, 2315-2321. https://doi.org/10.1016/j.ejca.2011.06.007
[31]
Huang, J., Yu, N., Wang, X. and Long, X. (2017) Incidence of Lower Limb Lymphedema after Vulvar Cancer: A Systematic Review and Meta-Analysis. Medicine, 96, e8722. https://doi.org/10.1097/MD.0000000000008722
[32]
Van der Zee, A.G., Oonk, M.H., De Hullu, J.A., Ansink, A.C., Vergote, I., Verheijen, R.H., Maggioni, A., Gaarenstroom, K.N., Baldwin, P.J., Van Dorst, E.B., Van der Velden, J., Hermans, R.H., van der Putten, H., Drouin, P., Schneider, A. and Sluiter, W.J. (2008) Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer. Journal of Clinical Oncology, 26, 884-889. https://doi.org/10.1200/JCO.2007.14.0566
[33]
de Hullu, J.A., Oonk, M.H., Ansink, A.C., Hollema, H., Jager, P.L. and van der Zee, A.G. (2004) Pitfalls in the Sentinel Lymph Node Procedure in Vulvar Cancer. Gynecologic Oncology, 94, 10-15. https://doi.org/10.1016/j.ygyno.2004.02.031
[34]
Chapman, B.V., Gill, B.S., Viswanathan, A.N., Balasubramani, G.K., Sukumvanich, P. and Beriwal, S. (2017) Adjuvant Radiation Therapy for Margin-Positive Vulvar Squamous Cell Carcinoma: Defining the Ideal Dose-Response Using the National Cancer Data Base. International Journal of Radiation Oncology, Biology, Physics, 97, 107-117. https://doi.org/10.1016/j.ijrobp.2016.09.023
[35]
Tagliaferri, L., Lancellotta, V., Casà, C., Fragomeni, S.M., Ferioli, M., Gentileschi, S., Caretto, A.A., Corrado, G., Gui, B., Colloca, G.F., Gambacorta, M.A., Morganti, A.G., Garganese, G. and Macchia, G. (2021) The Radiotherapy Role in the Multidisciplinary Management of Locally Advanced Vulvar Cancer: A Multidisciplinary VulCan Team Review. Cancers, 13, Article 5747. https://doi.org/10.3390/cancers13225747
[36]
Bhatla, N., Tomar, S., Meena, J., Sharma, D.N. and Kumar, L. (2022) Adjuvant Treatment in Cervical, Vaginal and Vulvar Cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 78, 36-51. https://doi.org/10.1016/j.bpobgyn.2021.07.005
[37]
Oonk, M.H.M., Planchamp, F., Baldwin, P., Bidzinski, M., Brännström, M., Landoni, F., et al. (2017) European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer. International Journal of Gynecological Cancer, 27, 832-837. https://doi.org/10.1097/IGC.0000000000000975
[38]
Olawaiye, A.B., Cuello, M.A. and Rogers, L.J. (2021) Cancer of the Vulva: 2021 Update. International Journal of Gynecology & Obstetrics, 155, 7-18. https://doi.org/10.1002/ijgo.13881
[39]
Inrhaoun, H., Elghissassi, I., Gutierrez, M., Brain, E. and Errihani, H. (2012) Long Term Response to Erlotinib in a Patient with Recurrent Vulvar Carcinoma: Case Report and Review of Literature. Gynecologic Oncology Case Reports, 2, 119-120. https://doi.org/10.1016/j.gynor.2012.07.002
[40]
Horowitz, N.S., Olawaiye, A.B., Borger, D.R., Growdon, W.B., Krasner, C.N., Matulonis, U.A., Liu, J.F., Lee, J., Brard, L. and Dizon, D.S. (2012) Phase II Trial of Erlotinib in Women with Squamous Cell Carcinoma of the Vulva. Gynecologic Oncology, 127,141-146. https://doi.org/10.1016/j.ygyno.2012.06.028
